Toronto - Delayed Quote CAD

Theratechnologies Inc. (TH.TO)

3.4800

-0.1000

(-2.79%)

At close: April 17 at 3:59:29 PM EDT

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Theratechnologies Inc. (NASDAQ:THTX) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was characterized […]

Insider Monkey 16 hours ago

THTX

^RUT

COMP
Theratechnologies Down 5.6% in U.S. Pre-market After Updating on Sale Process

Theratechnologies (TH.TO and NASDAQ: THTX), a commercial-stage biopharmaceutical company, overnight

PREMIUM
MT Newswires 3 days ago

THTX
Theratechnologies Provides Update on Sale Process

MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with

GlobeNewswire 3 days ago

THTX
Theratechnologies up 22% in U.S. Pre-market Trading, Confirms Buy-out Proposals

Theratechnologies (TH.TO, THTX) was at last look up 22% at fresh 52 week high levels in U.S. pre-mar

PREMIUM
MT Newswires 4 days ago

THTX
Future Pak submits proposals to acquire Theratechnologies

Future Pak announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies (THTX). The most recent proposal, which remains open for consideration by Theratechnologies and its Board of Directors, offers a cash consideration of $3.51-$4.50 per share. The proposal represents a total enterprise value of up to $255M, comprising: $205 million in cash at closing, and Up to $50 million in contingent value right payments, including

TipRanks 6 days ago

THTX
Soleus Capital Issues Letter to The Board of Theratechnologies

GREENWICH, Conn., April 12, 2025--Soleus Capital Management, L.P. ("Soleus Capital"), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ: THTX) (the "Company"), today sent a letter to the Board of Directors of the Company.

Business Wire 6 days ago

THTX
Theratechnologies Up 20% In US After Hours As Announces Exclusive Discussions with Another Potential Acquiror

Theratechnologies Inc. (TH.TO and NASDAQ: THTX), a commercial-stage biopharmaceutical company, was a

PREMIUM
MT Newswires 7 days ago

THTX
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in response to a press release issued today by Future Pak, LLC (“Future Pak”) regarding its proposals to acquire the Company. The Company believes its shareholders should be aware of the following: In August 2024, the Company received a first unsolicited non-binding proposal from Futur

GlobeNewswire 7 days ago

THTX
Theratechnologies Shares Jump 42% After Future Pak's $255 Million Takeover Bid

The offer includes $205 million in cash and up to $50 million in contingent payments.

GuruFocus.com 7 days ago

THTX
Theratechnologies Receives Buyout Offer from Future Pak at $3.51 to $4.50 per Share

Future Pak LLC said Friday that it submitted a formal proposal to acquire all of the outstanding com

PREMIUM
MT Newswires 7 days ago

THTX
Theratechnologies Inc (THTX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Theratechnologies Inc (THTX) reports a 17% revenue increase and outlines strategic plans to navigate market challenges and product transitions.

GuruFocus.com 9 days ago

THTX
Theratechnologies Swings to Q1 Profit as Sales Advance

Theratechnologies (TH.TO) on Wednesday said it swung to a first-quarter profit as revenue surged 17%

PREMIUM
MT Newswires 9 days ago

THTX
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLALatest from VAMOS study demonstrates excess visceral abdominal fat drives cardiovascular risk MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopha

GlobeNewswire 9 days ago

THTX
Theratechnologies Receives FDA Approval for EGRIFTA SV

Theratechnologies (TH.TO) on Tuesday said the U.S. Food and Drug Administration (FDA) has approved E

PREMIUM
MT Newswires 10 days ago

THTX
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all manufactured batches PAS approval follows recent FDA approval of new formulation, EGRIFTA WR™ MONTREAL, April 08, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Prior Approval Supplement (PAS

GlobeNewswire 11 days ago

THTX
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET. The call will be hosted by Paul Lévesque, President and Chief Executive Officer, who will be joined by other members of the management team, i

GlobeNewswire 15 days ago

THTX
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection. The Company will commercialize the new formulation under the tradename EG

GlobeNewswire 24 days ago

THTX
Theratechnologies Presents Ibalizumab Data in Virologic Suppression

Theratechnologies (TH.TO) on Wednesday presented data demonstrating ibalizumab's (sold under the bra

PREMIUM
MT Newswires last month

THTX
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily treatment-experienced people with multidrug resistant HIV MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmace

GlobeNewswire last month

THTX
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Study Demonstrates Excess Visceral Abdominal Fat Drives CV RiskMONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data highlighting the limitations of using body mass index (BMI) alone in assessing cardiovascular (CV) risk in people with HIV (PWH). The study underscores the need to incorporate screening for excess visceral abdominal fat (EVAF) to better

GlobeNewswire last month

THTX

Performance Overview

Return	TH.TO	S&P/TSX Composite index (^GSPTSE)
YTD	+33.33%	-1.74%
1-Year	+93.33%	+11.71%
3-Year	-74.18%	+10.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Theratechnologies Inc. (TH.TO)

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

Theratechnologies Down 5.6% in U.S. Pre-market After Updating on Sale Process

Theratechnologies Provides Update on Sale Process

Theratechnologies up 22% in U.S. Pre-market Trading, Confirms Buy-out Proposals

Future Pak submits proposals to acquire Theratechnologies

Soleus Capital Issues Letter to The Board of Theratechnologies

Theratechnologies Up 20% In US After Hours As Announces Exclusive Discussions with Another Potential Acquiror

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies Shares Jump 42% After Future Pak's $255 Million Takeover Bid

Theratechnologies Receives Buyout Offer from Future Pak at $3.51 to $4.50 per Share

Theratechnologies Inc (THTX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Theratechnologies Swings to Q1 Profit as Sales Advance

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval for EGRIFTA SV

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies Presents Ibalizumab Data in Virologic Suppression

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Performance Overview